These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32319167)

  • 21. [HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?].
    Oda Y; Washio K; Mizuno M; Imamura S; Nishigori C; Fukunaga A
    Arerugi; 2021; 70(9):1196-1199. PubMed ID: 34759084
    [No Abstract]   [Full Text] [Related]  

  • 22. Omalizumab in chronic inducible urticaria: A retrospective, real-life study.
    Fialek M; Dezoteux F; Le Moing A; Karimova E; Ramdane N; Pape E; Azib-Meftah S; Staumont-Sallé D
    Ann Dermatol Venereol; 2021 Dec; 148(4):262-265. PubMed ID: 34247853
    [No Abstract]   [Full Text] [Related]  

  • 23. Pityriasis rosea during omalizumab treatment for chronic spontaneous urticaria.
    Vaccaro M; Marafioti I; Cannavò SP; Ciccarese G; Drago F
    Dermatol Ther; 2020 Nov; 33(6):e14356. PubMed ID: 33009684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria.
    Castagna J; Bernard L; Hacard F; Delcroix F; Darrigade AS; Nicolas JF; Decullier E; Nosbaum A; Bérard F
    Br J Dermatol; 2020 Dec; 183(6):1124-1126. PubMed ID: 32531805
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of omalizumab treatment on serum cytokine concentrations of atopic patients with chronic spontaneous urticaria: a preliminary report.
    Sellitto A; De Fanis U; Balestrieri A; Savoia A; Astarita C; Romano C
    Eur Ann Allergy Clin Immunol; 2017 Jul; 49(4):171-175. PubMed ID: 28752720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticaria.
    Al-Shaikhly T; MacDonald JW; Bammler TK; Altman MC; Ayars AG; Petroni DH; Tilles SA; Henderson WR
    Allergy; 2021 Apr; 76(4):1274-1277. PubMed ID: 33314187
    [No Abstract]   [Full Text] [Related]  

  • 27. Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience.
    Akdaş E; Adışen E; Öztaş MO; Aksakal AB; İlter N; Gülekon A
    An Bras Dermatol; 2023; 98(2):240-242. PubMed ID: 36567165
    [No Abstract]   [Full Text] [Related]  

  • 28. Omalizumab improves perceived stress, anxiety, and depression in chronic spontaneous urticaria.
    Patella V; Zunno R; Florio G; Palmieri M; Palmieri S; Brancaccio R
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1402-1404. PubMed ID: 33248284
    [No Abstract]   [Full Text] [Related]  

  • 29. Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study.
    Di Bona D; Nettis E; Bilancia M; Ridolo E; Minenna E; Nizi MC; Albanesi M; Caiaffa MF; Macchia L
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2482-2485.e2. PubMed ID: 33677081
    [No Abstract]   [Full Text] [Related]  

  • 30. A very low number of circulating basophils is predictive of a poor response to omalizumab in chronic spontaneous urticaria.
    Rijavec M; Košnik M; Koren A; Kopač P; Šelb J; Vantur R; Kogovšek Ž; Bizjak M; Bajrović N; Zidarn M; Korošec P
    Allergy; 2021 Apr; 76(4):1254-1257. PubMed ID: 32876979
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug.
    Asero R
    Allergy; 2018 Nov; 73(11):2242-2244. PubMed ID: 29989179
    [No Abstract]   [Full Text] [Related]  

  • 32. Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature.
    Passanisi S; Arasi S; Caminiti L; Crisafulli G; Salzano G; Pajno GB
    Dermatol Ther; 2020 Jul; 33(4):e13489. PubMed ID: 32358910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria.
    Lal Vijayalal S; Arora S; Dabas R; Janney MS; Jankal Basavarajappa S; Das NM
    Dermatol Ther; 2020 Nov; 33(6):e14397. PubMed ID: 33040395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria.
    Baumann K; Jørgensen AR; Sørensen JA; Zhang DG; Ghazanfar MN; Skov PS; Woetmann A; Vestergaard C; Maurer M; Thomsen SF
    Clin Exp Allergy; 2023 Dec; 53(12):1318-1321. PubMed ID: 37771063
    [No Abstract]   [Full Text] [Related]  

  • 35. "Omalizumab plus": Combining omalizumab with immunosuppression for treatment of refractory chronic urticaria: A multicenter UK series.
    Rutkowski K; Wagner A; Jui-Lin Choo K; Smith H; Savic S; Grattan CE
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1400-1401.e2. PubMed ID: 33181342
    [No Abstract]   [Full Text] [Related]  

  • 36. Effectiveness of Omalizumab in Patients with Chronic Inducible Urticaria: real-life experience from two UCARE centres.
    Can PK; Salman A; Hoşgören-Tekin S; Kocatürk E
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e679-e682. PubMed ID: 34013560
    [No Abstract]   [Full Text] [Related]  

  • 37. Effective omalizumab interval prolongation in the treatment of chronic urticaria.
    Alizadeh Aghdam M; Pieterse RH; Kentie PA; Rijken F; Knulst AC; Röckmann H
    J Allergy Clin Immunol Pract; 2020; 8(10):3667-3668.e1. PubMed ID: 32679351
    [No Abstract]   [Full Text] [Related]  

  • 38. Omalizumab-induced triphasic anaphylaxis in a patient with chronic spontaneous urticaria.
    Gönül M; Özenergün Bittacı A; Ergin C
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e135-e136. PubMed ID: 26446412
    [No Abstract]   [Full Text] [Related]  

  • 39. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
    Salman A; Ergun T; Gimenez-Arnau AM
    J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
    [No Abstract]   [Full Text] [Related]  

  • 40. Development of angio-oedema after omalizumab injections in a patient with chronic spontaneous urticaria.
    Magen E; Chikovani T
    Clin Exp Dermatol; 2018 Oct; 43(7):825. PubMed ID: 29777532
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.